When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
LiveXLive Media
The Trade: LiveXLive Media, Inc. (NASDAQ: LIVX) CEO and Chairman Robert S Ellin acquired a total of 43654 shares at an average price of $2.79. To acquire these shares, it cost $27,852.00.
What’s Happening: The company, last week, posted a wider-than-expected quarterly loss.
What LiveXLive Media Does: LiveXLive Media Inc is the premium internet networks devoted to live music and music-related video content.
Presidio Property Trust
The Trade: Presidio Property Trust, Inc. (NASDAQ: SQFT) CEO and President Kendrick Jack Heilbron acquired a total of 1300 shares shares at an average price of $3.56. The insider spent $4,632.00 to buy those shares.
What’s Happening: Presidio Property Trust, last week, reported Q2 core FFO of $0.08.
What Presidio Property Trust Does: Presidio Property Trust Inc is a real estate company.
PHX Minerals
The Trade: PHX Minerals Inc. (NYSE: PHX) 10% owner Edenbrook Capital Llc, Jonathan Brolin acquired a total of 144311 shares at an average price of $2.73. To acquire these shares, it cost $394,686.09.
What’s Happening: PHX Minerals, recently, reported a loss for its third quarter.
What PHX Minerals Does: PHX Minerals, previously Panhandle Oil & Gas, is an oil and natural gas mineral company that has employed a strategy to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership.
DiaMedica Therapeutics
The Trade: DiaMedica Therapeutics Inc. (NASDAQ: DMAC) Director Amy Burroughs acquired a total of 44950 shares shares at an average price of $3.15. The insider spent $141,592.50 to buy those shares.
What’s Happening: DiaMedica Therapeutics, recently, posted a narrower-than-expected quarterly loss.
What DiaMedica Therapeutics Does: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company.
See more from Benzinga
Click here for options trades from Benzinga
Mid-Morning Market Update: Markets Mixed; Target Reports Upbeat Profit
5 Stocks Insiders Are Selling
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
